Sudeep Pharma had a robust debut on the stock exchanges, opening more than 23% higher than its IPO price. The Rs 895-crore issue, oversubscribed by a remarkable 93.71 times from November 21 to 25, commenced trading at Rs 730 on the NSE and Rs 725 on the BSE, surpassing the IPO price of Rs 593 and establishing a market capitalization of about Rs 8,188 crore.
The listing outperformed the grey-market projections of a 20% premium. Prior to its market debut, Sudeep Pharma secured Rs 268.5 crore from anchor investors, underscoring the strong institutional interest in the offering.
Specializing in mineral-based excipients and specialty ingredients for pharmaceuticals, nutraceuticals, and food products, Sudeep Pharma produces a range of essential salts like calcium, magnesium, iron, and others utilized in tablets, supplements, and fortified foods. With operations across multiple plants, including a significant facility in Nandesari, Gujarat, the company exports to various international markets, positioning itself with enduring visibility in vital pharmaceutical and nutrition supply chains.
The IPO consisted of a fresh issue of Rs 95 crore and an offer-for-sale of Rs 800 crore by existing shareholders. A portion of the proceeds, amounting to Rs 75.8 crore, is earmarked for acquiring new machinery for the Nandesari Facility 1 production line, while the rest will support general corporate needs.
Market observers highlighted that Sudeep Pharma’s strong debut reflects its solid fundamentals, global demand for excipients, and the broader investor interest in technology-driven manufacturing enterprises. The company’s impressive financial performance, healthy margins, and extensive export reach were pivotal factors in the high subscription rate.
The successful listing coincides with a period of subdued valuations in the broader market following a phase of consolidation, creating an opportunity for quality mid-sized companies like Sudeep Pharma to attract investor attention.